Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

243.05USD
4:01pm EDT
Change (% chg)

$3.55 (+1.48%)
Prev Close
$239.50
Open
$240.00
Day's High
$243.23
Day's Low
$239.89
Volume
570,046
Avg. Vol
837,909
52-wk High
$261.27
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Allergan partners with Target Pharmasolutions to advance NASH research
Thursday, 20 Apr 2017 09:00am EDT 

April 20 (Reuters) - Allergan Plc :Allergan partners with Target Pharmasolutions to advance NASH research.Allergan-Target-Nash is 5-year longitudinal observational study, looks at patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis.  Full Article

Argentum Pharmaceuticals, Allergan settle patent dispute over Restasis
Tuesday, 18 Apr 2017 04:01pm EDT 

April 18 (Reuters) - Allergan Plc :Argentum PHARMACEUTICALS and Allergan settle patent dispute over Restasis.Argentum Pharmaceuticals - specific date on which Argentum may launch generic product and other details concerning settlement have not been disclosed.Argentum Pharmaceuticals- agreement generally provides Argentum may commence marketing generic equivalent product sometime prior to expiration of patents covering Restasis.  Full Article

Prospect Park Capital says will not receive milestone payment held onto upon sale of interest in IOI
Wednesday, 29 Mar 2017 12:43pm EDT 

Prospect Park Capital Corp : Says advised by Serenity Pharmaceuticals co will not receive milestone payment which it held onto upon sale of interest in IOI . Says prospect park's final return on its investment in IOI remains at 8%. .Will not receive payment in light of Allergan exercising unilateral right to terminate license, transfer, development agreement with Serenity.  Full Article

Allergan and Paratek announce positive results from two phase 3 trials of sarecycline
Monday, 27 Mar 2017 07:31am EDT 

Allergan Plc : Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne . Allergan Plc - plans to file a new drug application (NDA) to U.S. Food & drug administration (fda) in second half of this year . On track for FDA submission in second half of 2017 .Sarecycline was statistically significantly superior to placebo with respect to primary efficacy endpoints.  Full Article

Allergan and Paratek announce positive results from two phase 3 trials
Monday, 27 Mar 2017 07:30am EDT 

Paratek Pharmaceuticals Inc : Allergan and Paratek announce positive results from two phase 3 trials of sarecycline for the treatment of moderate to severe acne . Paratek Pharmaceuticals - two phase 3 trials of sarecycline for treatment of moderate to severe acne met their 12 week primary efficacy endpoints .Paratek Pharmaceuticals says Allergan plans to file a new drug application (NDA) to U.S. Food & Drug Administration (FDA) in second half of this year.  Full Article

Allergan reports availability of restasis multidose
Wednesday, 22 Mar 2017 07:31am EDT 

Allergan Plc : Allergan announces availability of restasis multidose™ (cyclosporine ophthalmic emulsion) 0.05 pct -- the first fda-approved preservative free prescription eye drop available in a multidose bottle .Allergan Plc - availability of restasis multidose, which is same preservative-free restasis® formulation, but now offered in a multidose bottle.  Full Article

Juvéderm Vollure XC approved by FDA for correction of facial wrinkles and folds
Monday, 20 Mar 2017 07:31am EDT 

Allergan Plc : Juvéderm Vollure™ XC approved by U.S. FDA for correction of facial wrinkles and folds in adults over the age of 21 .Allergan- Received approval from U.S. FDA to market Juvéderm Vollure XC, for correction of facial wrinkles and folds in adults over age of 21.  Full Article

Allergan and Editas Medicine enter into strategic research and development alliance
Tuesday, 14 Mar 2017 08:00am EDT 

Allergan Plc : Allergan and Editas Medicine enter into strategic research and development alliance to discover and develop Crispr Genome editing medicines for eye diseases . Under terms of agreement, Editas medicine will receive an upfront payment of $90 million for development of five candidate programs . Editas Medicine has potential to earn additional payments for achieving important near-term milestones specifically related to LCA10 . Editas medicine will also be eligible to receive development and commercial milestones, as well as royalty payments on a per-program basis .Allergan will have option to license up to five programs and will be responsible for development and commercialization of optioned products.  Full Article

FDA accepts supplemental new drug application (SNDA) for vraylar
Wednesday, 8 Mar 2017 08:00am EST 

Allergan Plc : FDA accepts supplemental new drug application (SNDA) for vraylar (cariprazine) .Application seeks to expand vraylar label to include Phase 3 clinical data for maintenance treatment of schizophrenia.  Full Article

Zeltiq Aesthetics posts Q4 profit of $0.25/share
Wednesday, 1 Mar 2017 04:17pm EST 

Zeltiq Aesthetics Inc : Zeltiq announces fourth quarter and full year 2016 financial results . Q4 revenue $105.1 million versus i/b/e/s view $102.4 million . Company is no longer providing 2017 financial guidance . Will also not be hosting a Q4 conference call, due to definitive agreement to be acquired by Allergan . Qtrly net income per share $0.25 .Q4 earnings per share view $0.17 -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

Photo

India watchdog orders antitrust probe into Roche cancer drug

MUMBAI India's antitrust regulator has ordered a probe into Swiss drugmaker Roche for allegedly using anti-competitive practices to restrict cheaper copies of a blockbuster cancer drug from reaching patients.